Proteomic analysis in Alzheimer's disease will help reveal specific early biomarkers and new therapeutic targets by studyng protein alterations that contribute to the aggregation and formation of plaques that damage neurons, contributing to neurodegeneration and memory loss. Research has identified the affected proteins that become hyperphosphorylated and accumulate in neurofibrillary tangles, disrupting synaptic interaction in neuronal cells. Among these, the most recently identified protein id DNA-PK, which, when inhibited by excess beta-amyloid, is unable to repair DNA damage, leading to neuronal necrosis. An imaging analysia, coordinated by Prescott and colleagues, published in Neuroscience highlighted that in asymptomatic carriers of autosomal dominant mutations, present on the long arm of chromosome 21, the structural connectivity of the white matter is altered compared to non-carriers. Research and technological innovation are the strategic tools and fundamental prerequisites to ensure the clinical appropiateness of Alzheimer's disease, in order to consider an overview of the topics of interest related to proteomics, biology, biotechnology, genetic engineering useful for also deepening the therapeutic efficacy.
Proteomics in Alzheimer's disease.Scientific evidence.Research protocols
Lepore,Maria Antonietta
2025
Abstract
Proteomic analysis in Alzheimer's disease will help reveal specific early biomarkers and new therapeutic targets by studyng protein alterations that contribute to the aggregation and formation of plaques that damage neurons, contributing to neurodegeneration and memory loss. Research has identified the affected proteins that become hyperphosphorylated and accumulate in neurofibrillary tangles, disrupting synaptic interaction in neuronal cells. Among these, the most recently identified protein id DNA-PK, which, when inhibited by excess beta-amyloid, is unable to repair DNA damage, leading to neuronal necrosis. An imaging analysia, coordinated by Prescott and colleagues, published in Neuroscience highlighted that in asymptomatic carriers of autosomal dominant mutations, present on the long arm of chromosome 21, the structural connectivity of the white matter is altered compared to non-carriers. Research and technological innovation are the strategic tools and fundamental prerequisites to ensure the clinical appropiateness of Alzheimer's disease, in order to consider an overview of the topics of interest related to proteomics, biology, biotechnology, genetic engineering useful for also deepening the therapeutic efficacy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
